Analysts take a look at Circassia Pharmaceuticals Plc (LON:CIR) having this to say.

April 5, 2018 - By Marguerite Chambers

Circassia Pharmaceuticals Plc (LON:CIR) LogoInvestors sentiment increased to 1.02 in 2017 Q4. Its up 0.02, from 1 in 2017Q3. It is positive, as 7 investors sold Circassia Pharmaceuticals Plc shares while 37 reduced holdings. 12 funds opened positions while 33 raised stakes. 16.91 million shares or 4.21% more from 16.23 million shares in 2017Q3 were reported.
The Texas-based Teacher Retirement System Of Texas has invested 0% in Circassia Pharmaceuticals Plc (LON:CIR). Zurcher Kantonalbank (Zurich Cantonalbank) has 0% invested in Circassia Pharmaceuticals Plc (LON:CIR) for 1,355 shares. Jpmorgan Chase holds 0% in Circassia Pharmaceuticals Plc (LON:CIR) or 30,141 shares. Comerica Savings Bank, a Michigan-based fund reported 16,966 shares. Great West Life Assurance Can, Manitoba – Canada-based fund reported 19,922 shares. Parallax Volatility Advisers Lp, California-based fund reported 2,520 shares. Bank & Trust Of New York Mellon Corporation accumulated 0% or 191,504 shares. Parkside Natl Bank Trust reported 0% stake. Legal & General Group Inc Inc Pcl accumulated 31,119 shares. Ameritas Investment Ptnrs has 1,323 shares. Gamco Invsts Incorporated Et Al holds 0.43% or 1.43 million shares. State Of Tennessee Treasury Department reported 13,070 shares stake. Pub Employees Retirement Of Ohio reported 0% in Circassia Pharmaceuticals Plc (LON:CIR). Wells Fargo And Mn reported 0% of its portfolio in Circassia Pharmaceuticals Plc (LON:CIR). 5,700 are owned by Teachers Retirement Systems Of The State Of Kentucky.

Circassia Pharmaceuticals Plc (LON:CIR) Ratings Coverage

Among 2 analysts covering Circassia Pharmaceuticals Plc (LON:CIR), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Circassia Pharmaceuticals Plc had 5 analyst reports since October 31, 2017 according to SRatingsIntel. The stock of Circassia Pharmaceuticals Plc (LON:CIR) earned “Hold” rating by Peel Hunt on Thursday, January 4. The rating was maintained by Peel Hunt with “Hold” on Tuesday, October 31. The stock of Circassia Pharmaceuticals Plc (LON:CIR) has “Hold” rating given on Thursday, March 1 by Peel Hunt. Numis Securities maintained the stock with “Buy” rating in Monday, December 4 report. The rating was maintained by Peel Hunt on Thursday, February 1 with “Hold”. Below is a list of Circassia Pharmaceuticals Plc (LON:CIR) latest ratings and price target changes.

01/03/2018 Broker: Peel Hunt Rating: Hold Old Target: GBX 130.00 New Target: GBX 130.00 Maintain
01/02/2018 Broker: Peel Hunt Rating: Hold Old Target: GBX 130.00 New Target: GBX 130.00 Maintain
04/01/2018 Broker: Peel Hunt Rating: Hold Old Target: GBX 130.00 New Target: GBX 130.00 Maintain
04/12/2017 Broker: Numis Securities Rating: Buy Old Target: GBX 180.00 New Target: GBX 180.00 Maintain
31/10/2017 Broker: Peel Hunt Rating: Hold Old Target: GBX 130.00 New Target: GBX 130.00 Maintain

The stock decreased 0.45% or GBX 0.4 during the last trading session, reaching GBX 89.3. About 6,097 shares traded. Circassia Pharmaceuticals Plc (LON:CIR) has 0.00% since April 5, 2017 and is . It has underperformed by 11.55% the S&P500.

Circassia Pharmaceuticals plc, a specialty biopharmaceutical company, focuses on the development and commercialization of products for the treatment of asthma and chronic obstructive pulmonary disease . The company has market cap of 297.79 million GBP. It markets novel NIOX asthma management products directly to specialists in the United States, the United Kingdom, and Germany, as well as through a network of partners internationally. It currently has negative earnings. The companyÂ’s asthma products comprise Fliveo that targets substitution of Flixotide, which has approved in the United Kingdom, as well as developing Seriveo that targets direct substitution of Seretide.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.